
Wednesday, May 07, 2025 2:48:07 AM
So again...
Setting the Record Straight (Again) on GRST, the Reg A Offering, and Reverse Split Claims
Let’s address this poster’s recycled narrative — again — with actual facts:
1. The Regulation A offering is OFF the table. Period.
Yes, the company initially filed a Reg A offering in 2024. It was part of a capital raise strategy that didn’t materialize, and Mr. Leon has confirmed directly that the Reg A is no longer being pursued. This is not speculation — it’s a direct statement. Repeating outdated info doesn’t make it true.
2. Mr. Leon purchased 53% of the outstanding shares — that’s a FACT, not a red flag.
When outside capital didn’t come in, he stepped in and put his own money on the line. That’s not a “Ponzi” move — that’s ownership, commitment, and skin in the game. He didn’t dump shares, he accumulated them.
3. The reverse split (RS) is NOT about dilution.
This is a key point: GRST has not done a reverse split in over 20 years, and this move is being considered solely to enable a move to a higher exchange — not to dilute shareholders indiscriminately.
In fact, the RS can position the company for greater institutional investment and make debt repayment more efficient — not to “keep the Ponzi going,” as falsely claimed.
4. Debt = Friendly, Not Toxic.
The so-called "$5M in preferred shares” is not some sinister vehicle. These are disclosed and categorized as friendly debt from insiders and long-term advisors — not vulture funds looking to flip toxic notes. There is no death-spiral lending structure here.
5. Promotion ? Deception.
Yes, GRST promoted the Reg A opportunity earlier in 2024, including through interviews and media content. That’s what companies seeking growth capital do. The use of proceeds was transparently disclosed — and when the Reg A didn’t go through, GRST pivoted. That’s not deception — that’s adaptation.
So let’s cut through the noise.
This poster is not offering new insights. He’s looping old, publicly known facts with dramatic language and conspiracy-laced spins. The Markowski podcast may have had production flaws — but that doesn’t invalidate the company’s strategy or filings. Nor does it justify calling a small-cap recovery company a “Ponzi scheme.” That crosses the line from criticism to deliberate misrepresentation.
Anyone who actually reads the filings knows where GRST stands — and where it’s heading.

Recent GRST News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2025 01:26:13 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 01/10/2025 10:04:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2025 10:04:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/23/2024 01:21:05 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 10:19:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2024 07:59:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:46:15 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 07:23:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/29/2024 05:40:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/29/2024 05:39:45 PM
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM